v3.19.3.a.u2

Grants (Details) | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | ---
Mar. 31, 2019 USD ($) | Sep. 30, 2016 USD ($) | Jan. 31, 2016 USD ($) | Oct. 31, 2013 USD ($) | Dec. 31, 2019 USD ($) contract_option | Sep. 30, 2019 USD ($) | Jun. 30, 2019 USD ($) | Mar. 31, 2019 USD ($) | Dec. 31, 2018 USD ($) | Sep. 30, 2018 USD ($) | Jun. 30, 2018 USD ($) | Mar. 31, 2018 USD ($) | Dec. 31, 2019 USD ($) contract_option | Dec. 31, 2018 USD ($) | Dec. 31, 2017 USD ($)
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  | $ 14,055,000 | $ 17,046,000 | $ 13,083,000 | $ 16,025,000 | $ 35,421,000 | $ 41,757,000 | $ 28,851,000 | $ 29,039,000 | $ 60,209,000 | $ 135,068,000 | $ 205,825,000
Deferred revenue |  |  |  |  | 199,528,000 |  |  |  | 240,924,000 |  |  |  | 199,528,000 | 240,924,000 |
Grant revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  |  |  |  |  |  |  |  |  | 12,173,000 | 12,556,000 | 28,851,000
BARDA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Award amount |  | $ 125,800,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Amount committed for funding |  |  |  |  | 117,300,000 |  |  |  |  |  |  |  | 117,300,000 |  |
Available funding |  |  |  |  | $ 8,500,000 |  |  |  |  |  |  |  | $ 8,500,000 |  |
BARDA | Initial base award |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Award amount |  | 8,200,000 |  |  |  |  |  |  |  |  |  |  |  |  |
BARDA | Contract options |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Award amount |  | $ 117,600,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Number of contract options exercised | contract_option |  |  |  |  | 3 |  |  |  |  |  |  |  | 3 |  |
Number of contract options | contract_option |  |  |  |  | 4 |  |  |  |  |  |  |  | 4 |  |
BARDA | Grant revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  |  |  |  |  |  |  |  |  | $ 7,600,000 | 6,800,000 | 20,100,000
The Bill & Melinda Gates Foundation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Award amount |  |  | $ 100,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |
Available funding |  |  |  |  | $ 80,000,000 |  |  |  |  |  |  |  | 80,000,000 |  |
Deferred revenue |  |  |  |  | 1,500,000 |  |  |  | 800,000 |  |  |  | 1,500,000 | 800,000 |
The Bill & Melinda Gates Foundation | Initial project |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Award amount | $ 1,100,000.0 |  | $ 20,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |
Amount committed for funding |  |  |  |  | 21,100,000 |  |  |  |  |  |  |  | 21,100,000 |  |
The Bill & Melinda Gates Foundation | Grant revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  |  |  |  |  |  |  |  |  | 3,400,000 | 1,400,000 | 1,100,000
DARPA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Award amount |  |  |  | $ 24,600,000 |  |  |  |  |  |  |  |  | 19,700,000 |  |
Amount committed for funding |  |  |  |  | $ 19,700,000 |  |  |  | $ 19,700,000.0 |  |  |  | 19,700,000 | 19,700,000.0 |
DARPA | Grant revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  |  |  |  |  |  |  |  |  | $ 500,000 | $ 3,500,000 | $ 7,700,000

X
- Definition Revenue From Grants, Current Funding Capacity + References No definition available. + Details
Name: | mrna_RevenueFromGrantsCurrentFundingCapacity
Namespace Prefix: | mrna_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue From Grants, Maximum Award + References No definition available. + Details
Name: | mrna_RevenueFromGrantsMaximumAward
Namespace Prefix: | mrna_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue From Grants, Number Of Contract Options + References No definition available. + Details
Name: | mrna_RevenueFromGrantsNumberOfContractOptions
Namespace Prefix: | mrna_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Revenue From Grants, Number Of Contract Options Exercised + References No definition available. + Details
Name: | mrna_RevenueFromGrantsNumberOfContractOptionsExercised
Namespace Prefix: | mrna_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Revenue From Grants, Remaining Funding Capacity + References No definition available. + Details
Name: | mrna_RevenueFromGrantsRemainingFundingCapacity
Namespace Prefix: | mrna_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_GrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_InitialBaseAwardMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_ContractOptionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mrna_TheBillAndMelindaGatesFoundationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_InitialProjectMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mrna_DefenseAdvancedResearchProjectsAgencyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |